Data integrity in drug approval processes is critical to public health safety. Examine the adequacy of India's current enforcement mechanisms under the Drugs and Cosmetics Act, 1940.

Q. Data integrity in drug approval processes is critical to public health safety. Examine the adequacy of India's current enforcement mechanisms under the Drugs and Cosmetics Act, 1940. (15 marks, 250-350 words)

Regulatory approval of a drug rests entirely on the dossier the applicant submits; fabricated manufacturing, stability or bio-equivalence data therefore converts a safety gatekeeping process into a paper formality. India's enforcement architecture under the Drugs and Cosmetics Act, 1940 has been progressively strengthened, but remains only partially adequate.

Existing enforcement framework - The Act of 1940 and the Drugs Rules, 1945 govern import, manufacture, distribution and sale, prescribing standards, licensing and penal consequences [2][3]. - CDSCO under MoHFW sets central standards and approvals, while State Licensing Authorities issue and enforce most manufacturing and sale licences — a federal, two-tier design [3]. - Traditional tools against false data were application-specific: rejection of the application and cancellation of the licence [1].

Recent strengthening: the debarment power - G.S.R. 756(E), dated 16 October 2025 amends the Drugs Rules, 1945 to let the Licensing Authority debar further applications by entities submitting fake or fabricated data, across all application types under the Rules [1]. - It shifts enforcement from case-specific to entity-level sanction, deterring the earlier practice of simply refiling after rejection [1]. - Natural justice is preserved through a mandatory show-cause notice and a right of appeal [1].

Persisting inadequacies - Reform came via subordinate legislation, not amendment of the parent Act — penal deterrence under the 1940 Act itself is unchanged [1][2]. - Enforcement depends on uniform application by State drug controllers, whose capacity and inspection strength vary widely [3]. - Detecting fabrication needs proactive data audit and laboratory verification, not merely dossier scrutiny.

Overall, the framework is now conceptually sound but operationally uneven: the legal tools have caught up, institutional capacity has not. Harmonised central–state enforcement, risk-based data audits and strengthened testing infrastructure would convert the new debarment power into real deterrence, advancing the Article 21 guarantee of health and India's SDG-3 commitments while protecting its standing as the "pharmacy of the world".

(~320 words)

Sources: 1. PIB, MoHFW — Union Health Ministry Notifies Stricter Drugs Rules to Debar Applicants Submitting Fake or Fabricated Data (6 August 2026) — G.S.R. 756(E) dated 16.10.2025, debarment power, scope, show-cause and appeal, earlier rejection/cancellation-only regime 2. India Code — The Drugs and Cosmetics Act, 1940 (Act No. 23 of 1940) — parent statute, unchanged penal provisions 3. CDSCO — The Drugs and Cosmetics Act, 1940 and Rules, 1945 — regulatory scope, CDSCO and State Licensing Authority roles